Targets › PDCD1L1
3 programs from 3 companies in 3 trials: 3 Phase 2; Oncology; next expected readout Dec 2026.
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. (UniProt, Q9NZQ7)
Open in Phaseline: the race on PDCD1L1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | Tagitanlimab Anti-PD-L1 monoclonal antibody blocking PD-1/PD-L1 signaling | PDCD1L1 | Phase 2 | Resectable Head and Neck Squamous Cell Carcinoma | Dec 2026 |
| James Brugarolas | 89Zr-DFO-Atezolizumab PD-L1 imaging agent (radiolabeled anti-PD-L1 antibody) | PDCD1L1 | Phase 2 | Renal Cell Carcinoma | Aug 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Retlirafusp alfa Anti-PD-L1/TGF-β bifunctional fusion protein | PDCD1L1, TGFB1 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | Mar 2028 |
Resectable Head and Neck Squamous Cell Carcinoma (1) Renal Cell Carcinoma (1) Intrahepatic Cholangiocarcinoma (Icc) (1)
antibody (2), small molecule (1)
West China Hospital (1) James Brugarolas (1) The First Affiliated Hospital with Nanjing Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.